Abstract
Since the historical use of gonadotrophin and estradiol levels to define the different anovulatory disorders has shown some limitations, the use of other markers such as anti-müllerian hormone (AMH) has been proposed. This review addresses the role of AMH in the differential diagnosis of anovulatory disorders, especially focusing on its value in the prognostic characterization of their severity. Current limitations and future clinical applications are discussed.
Highlights
Anovulatory disorders in women can be various
World Health Organization (WHO) 1 anovulatory dysfunction, which accounts for 5–10% of all anovulatory disorders, is characterized by low gonadotrophin and low estradiol serum levels [2]
The Anti-Müllerian hormone (AMH), given its relationship with the follicular ovarian pool, is a reliable marker of ovarian reserve and its clinical use has recently been extended and emphasized. It has been proposed by different authors as a potential marker in the differential diagnosis of the various forms of anovulatory dysfunctions: it is usually normal in patients with hypogonadotropic anovulation, high in normogonadotropic anovulations and low in hypergonadotropic anovulations [2, 7, 15]
Summary
Since the historical use of gonadotrophin and estradiol levels to define the different anovulatory disorders has shown some limitations, the use of other markers such as antimüllerian hormone (AMH) has been proposed. This review addresses the role of AMH in the differential diagnosis of anovulatory disorders, especially focusing on its value in the prognostic characterization of their severity. Current limitations and future clinical applications are discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
